New Frontline BTK Inhibitor Strategy Gains FDA Approval in Untreated Mantle Cell Lymphoma
Pharmacy Times
JUNE 27, 2025
Because of its aggressive nature, MCL is typically treated with combination chemotherapy at diagnosis. November 21, 2019. For this application, the FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. healthbook TIMES Onco Hema. 2024;22(4):22-29. doi:10.36000/HBT.OH.2024.22.163
Let's personalize your content